Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MARCH 25, 2022
Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020. Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010-2018.
Let's personalize your content